According to a new report, published by KBV research, The Global Vaccine Adjuvants Market size is expected to reach $2.1 billion by 2030, rising at a market growth of 3.7% CAGR during the forecast period.
The Particulate segment is registering a CAGR of 3% during the forecast period. The substantial market share can be ascribed to an extensive assortment of products and enhanced efficacy in combating diseases. The particulate category comprises adjuvants like cytokines, alum, and virosomes. Alum is among the most widespread adjuvants for vaccines. Plasma-containing aluminum compounds find utility in vaccine formulations, including those for hepatitis B and HPV. Virosome particles, which are utilized as adjuvants in vaccines against influenza and hepatitis A, bear a resemblance to certain noninfectious viruses.
The Intramuscular segment led the Global Vaccine Adjuvants Market, by Administration in 2022; thereby, achieving a market value of $569.9 Million by 2030. The demand for intramuscular adjuvants is fueled by the need for more effective, accessible, and affordable vaccines. Intramuscular vaccine adjuvants are sought after because they enhance the body's immune response to vaccines. They stimulate the immune system, leading to a more robust and long-lasting immune reaction, which can be crucial in generating adequate protection against certain diseases.
The Infectious Diseases segment is growing at a CAGR of 3.5 % during the forecast period. The significant expansion can be attributed to the steadily rising prevalence of communicable diseases, such as influenza, malaria, hepatitis A, B, and C. In addition, robust pipeline products for infectious disease-related vaccine adjuvants are anticipated to drive market expansion in the coming years.
The North America region dominated the Global Vaccine Adjuvants Market, by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $836.8 Million by 2030. The Europe region is anticipated to grow at a CAGR of 3.6% during (2023 - 2030). Additionally, The Asia Pacific region would witness a CAGR of 4% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/vaccine-adjuvants-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country-wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of GlaxoSmithKline PLC, Novavax, Inc., SPI Pharma, Inc. (Associated British Foods PLC), Agenus Inc., CSL Limited, InvivoGen SAS, Croda International PLC, Seppic S.A. (L’Air Liquide S.A.), Merck & Co., Inc. and Riboxx GmbH
By Type
By Administration
By Application
By Geography
Companies Profiled
Unique Offerings 
